Evidence map›Paper›PMID 28406939›Full record

ArticlePloS one2017

Role of NeuroD1 on the negative regulation of Pomc expression by glucocorticoid.

Rehana Parvin, Akiko Saito-Hakoda, Hiroki Shimada, Kyoko Shimizu, Erika Noro, Yasumasa Iwasaki, Ken Fujiwara, Atsushi Yokoyama, Akira Sugawara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Differential Effects of Fkbp4 and Fkbp5 on Regulation of theInternational journal of molecular sciences · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rehana ParvinDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Akiko Saito-HakodaDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Hiroki ShimadaDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Kyoko ShimizuDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Erika NoroDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Yasumasa IwasakiHealth Service Center, Kochi University, Kochi, Kochi, Japan.
Ken FujiwaraDivision of Histology and Cell Biology, Department of Anatomy, Jichi Medical University School of Medicine, Tochigi, Japan.
Atsushi YokoyamaDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Akira SugawaraDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Tohoku University · JPJichi Medical University · JPKōchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanism of the negative regulation of proopiomelanocortin gene (Pomc) by glucocorticoids (Gcs) is still unclear in many points. Here, we demonstrated the involvement of neurogenic differentiation factor 1 (NeuroD1) in the Gc-mediated negative regulation of Pomc. Murine pituitary adrenocorticotropic hormone (ACTH) producing corticotroph tumor-derived AtT20 cells were treated with dexamethasone (DEX) (1-100 nM) and cultured for 24 hrs. Thereafter, Pomc mRNA expression was studied by quantitative real-time PCR and rat Pomc promoter (-703/+58) activity was examined by luciferase assay. Both Pomc mRNA expression and Pomc promoter activity were inhibited by DEX in a dose-dependent manner. Deletion and point mutant analyses of Pomc promoter suggested that the DEX-mediated transcriptional repression was mediated via E-box that exists at -376/-371 in the promoter. Since NeuroD1 is known to bind to and activate E-box of the Pomc promoter, we next examined the effect of DEX on NeuroD1 expression. Interestingly, DEX dose-dependently inhibited NeuroD1 mRNA expression, mouse NeuroD1 promoter (-2.2-kb) activity, and NeuroD1 protein expression in AtT20 cells. In addition, we confirmed the inhibitory effect of DEX on the interaction of NeuroD1 and E-box on Pomc promoter by chromatin immunoprecipitation (ChIP) assay. Finally, overexpression of mouse NeuroD1 could rescue the DEX-mediated inhibition of Pomc mRNA expression and Pomc promoter activity. Taken together, it is suggested that the suppression of NeuroD1 expression and the inhibition of NeuroD1/E-box interaction may play an important role in the Gc-mediated negative regulation of Pomc.

Indexed as

ACTH-Secreting Pituitary AdenomaAdenomaAnimalsBasic Helix-Loop-Helix ProteinsCell Line, TumorDexamethasoneDose-Response Relationship, DrugGene Expression Regulation, NeoplasticGlucocorticoidsMiceNeoplasm ProteinsPromoter Regions, GeneticPro-OpiomelanocortinRatsRNA, MessengerRNA, NeoplasmBasic Helix-Loop-Helix ProteinsDexamethasoneGlucocorticoidsNeoplasm ProteinsNeurod1 protein, mousePro-OpiomelanocortinRNA, MessengerRNA, Neoplasm

Identifiers

PMID28406939
PMCPMC5391015
OpenAlexW2606146738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.